ArticleDermatology and therapy2025
Cluster Analysis of Clinical Remission and Relapse Patterns in Chronic Urticaria: Results from the PREDICT-CU Study.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms.Asia Pacific allergy · 2026Review
- Predictive value of baseline hematological parameters for the risk of recurrence in chronic urticaria.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with chronic urticaria (CU) may have different clinical courses of disease including periods of active CU, clinical remission, and relapse. The objective of this study was to describe representative clinical remission and relapse profiles for patients with CU.
methodsAdults with a CU diagnosis and confirmation CU diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007-2018). Active CU was a period during which a patient was not in clinical remission. Clinical remission was defined as at least 12 months without CU diagnosis and/or treatment. Relapse was defined as having a CU diagnosis and/or treatment following clinical remission. A data-driven clustering algorithm grouped patients on the basis of clinical remission and relapse patterns.
resultsThe 112,443 patients were grouped into four clusters. Cluster 1 (N = 36,690 [32.6%]) had the shortest median time to clinical remission (4.1 months) and lowest relapse rate (38.0%). Cluster 2 (N = 29,834 [26.5%]) reached clinical remission later (10.0 months), with a higher relapse rate (52.3%). Clusters 3 (N = 24,093 [21.4%]) and 4 (N = 21,826 [19.4%]) had the longest median times to clinical remission (33.8 and 44.6 months) and highest relapse rates (75%). Cluster 4 had the most frequent CU diagnoses and treatments, and highest comorbidity burden, polypharmacy, and resource use.
conclusionsPatients in Clusters 3 and 4 had the lowest clinical remission and highest relapse rates relative to Clusters 1 and 2; additionally, Cluster 4 had higher resource use, more comorbidities, and polypharmacy. These cluster definitions could be used to develop a model to predict patients with relapsing and remitting patterns associated with higher disease burden who might require enhanced disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.